Search

everythinglearnresearchcommunity

for

Search:↓

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Ritlecitinib works well and is safe for treating alopecia areata.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Recognizing LET and AITD can help diagnose SLE early for better treatment.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Ritlecitinib is an effective new treatment for Alopecia Areata.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Tofacitinib may help treat Lichen Planopilaris, but more research is needed.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Bimekizumab can improve scarring alopecia in severe psoriasis.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Combining cetirizine and topical steroids can effectively manage severe lichen planus pilaris.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.